Demographic and clinical characteristics for the included 338 psoriatic arthritis patients
| N=338 | |
|---|---|
| Female, n | 194 (57.4%) |
| Age (years) | 54.3 (11.9) |
| Duration of psoriatic arthritis, (years) | 9.1 (7.1) |
| Body mass index (kg/m2) | 28.4 (4.63) |
| Daily smoking | 76 (22.5%) |
| C reactive protein (g/L) | 8.12 (9.45) |
| Erythrocyte sedimentation rate (ESR) (mm/h) | 12.6 (12.9) |
| Peripheral joint involvement | 325 (96.2%) |
| Only spinal joint involvement | 13 (3.8%) |
| MRI verified | 1 (7.7% of 13) |
| CT verified | 5 (38.5% of 13) |
| X-ray | 4 (30.7% of 13) |
| Both peripheral and spinal involvement | 91 (26.9%) |
| Palmoplantaris pustolosis | 27 (8%) |
| Nail involvement | 166 (49.1%) |
| Entesitis | 198 (58.6%) |
| Dactylitis | 73 (21.6%) |
| Colitis | 11 (3.3%) |
| Uveitis | 25 (7.4%) |
| Serology | |
| RF and/or anti-CCP negative | 238 (68.9%) |
| RF and/or anti-CCP positive | 9 (2.7%) |
| NA | 91 (26.9%) |
| HLA-B27 | |
| Negative | 41 (11.4%) |
| Positive | 28 (7.8%) |
| NA | 292 (80.9%) |
| Juxta-articular new bone formation on X-ray | 43.2 (43.2%) |
Continuous variables are presented as mean (SD) and categorical variables as numbers (percentage).
Anti-CCP, anticyclic citrullinated peptide antibodies; NA: not available; RF, rheumatoid factor; HLA-B27, human leukocyte antigen-B27.